Neuronetics Inc (STIM) posted $42 million in Q3 2026 revenue, expanded gross margin to 52.2%, and swung to positive adjusted EBITDA of $1.9 million, even as NeuroStar session revenue softened.
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.